Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|August 27, 2024

Advances in MDS Classification and Molecular Understanding

Author(s)Ryan Haumschild, PharmD, MS, MBA, James McCloskey, MD , Amer Zeidan, MD

After a brief introduction, medical experts discuss advances in MDS classification and molecular understanding.

Episodes in this series

EP. 1 Advances in MDS Classification and Molecular Understanding

EP. 1 Advances in MDS Classification and Molecular Understanding

EP. 2 Choosing MDS Therapies: Risk-Based Approaches

EP. 2 Choosing MDS Therapies: Risk-Based Approaches

EP. 3 Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial

EP. 3 Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial

EP. 4 ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in MDS

EP. 4 ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in MDS

EP. 5 Oral vs. Injectable HMAs: Convenience and Efficacy in Higher Risk MDS

EP. 5 Oral vs. Injectable HMAs: Convenience and Efficacy in Higher Risk MDS

EP. 6 HMA Persistence and Effectiveness in Higher Risk MDS

EP. 6 HMA Persistence and Effectiveness in Higher Risk MDS

EP. 7 Innovations and Future Directions in Higher Risk MDS Treatments

EP. 7 Innovations and Future Directions in Higher Risk MDS Treatments

EP. 8 Oral vs. Injectable HMAs: Patient Perspectives, Access, and IRA Impact

EP. 8 Oral vs. Injectable HMAs: Patient Perspectives, Access, and IRA Impact

EP. 9 Oral vs. IV HMAs: Considerations and Patient Guidance

EP. 9 Oral vs. IV HMAs: Considerations and Patient Guidance

EP. 10 Patient Feedback for MDS: Insights and Closing Remarks

EP. 10 Patient Feedback for MDS: Insights and Closing Remarks

Video content above is prompted by the following:

How has the new WHO (5th edition and ICC classification scheme for MDS impacted our understanding and management, particularly in distinguishing lower and higher risk categories?
How has our understanding of the molecular landscape of MDS evolved, and how does this knowledge inform personalized treatment approaches?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Trending on AJMC

Cicada COVID-19 Variant FAQs: Symptoms, Risk, and Prevention

INHALE-1 Findings Support Inhaled Insulin as a Viable Option for Pediatric Patients: Kevin Kaiserman, MD

AI Reshaping Diabetes Care From Nutrition to Clinical Decisions

Social Factors Shape Diabetes, Dementia Risk Across Populations

First FDA-Approved Inhaled Insulin for Kids Arrives With Mounting Data: Kevin Kaiserman, MD